Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients
| Autor: | Toshihiro Hamada, Masayuki Hirai, Masahiko Kato, Takehito Kondo, Yasutaka Yamamoto, Osamu Igawa, Haruaki Ninomiya, Einosuke Mizuta, Chiaki Shigemasa, Ichiro Hisatome, Kensaku Yamada |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Blood Glucose
Male medicine.medical_treatment Tetrazoles Pharmacology Benzoates Losartan Hydrochlorothiazide Double-Blind Method Drug Discovery medicine Humans Telmisartan Hyperuricemia Diuretics Antihypertensive Agents Thiazide Aged Chemistry Biphenyl Compounds Middle Aged medicine.disease Lipids Angiotensin II Uric Acid Candesartan Hypertension Benzimidazoles Female Diuretic Angiotensin II Type 1 Receptor Blockers medicine.drug |
| Zdroj: | Arzneimittelforschung. 60:71-75 |
| ISSN: | 1616-7066 0004-4172 |
| Popis: | A combination therapy of a low-dose antihypertensive diuretic with an angiotensin II receptor blocker (ARB) may have unfavorable effects on serum urate levels.Forty-two hypertensive patients without hyperuricemia (18 men and 24 women, mean age 65 years) were randomly divided into three groups. Each of the group was allocated to a combination therapy with losartan (LOS; CAS 124750-99-8; 50 mg/day)/hydrochlorothiazide (HCTZ; CAS 58-93-5; 12.5 mg/day) (LOS/HCTZ group), telmisartan (TEL; CAS 144701-48-4; 40 mg/day)/HCTZ (12.5 mg/day) (TEL/HCTZ group), or candesartan (CND; CAS 145040-37-5; 8 mg/day)/HCTZ (12.5 mg/day) (CND/HCTZ group), respectively. Before and after the treatment, blood pressure and biochemical parameters of blood and urine were evaluated.Both systolic and diastolic blood pressures significantly decreased in all groups (p0.01) without any statistical differences. The LOS/HCTZ group showed no changes in serum urate levels (5.8 +/- 1.0 mg/dl to 5.8 +/- 1.4 mg/dl) and in % fractional excretion of urate (FEUA). In the TEL/HCTZ group, the serum urate level was significantly increased, from 5.5 +/- 0.9 mg/dl to 6.5 +/- 1.2 mg/dl (p0.01), whereas FEUA significantly decreased (p0.01). Similarly, the CND/HCTZ group showed a significant increase in the serum urate level from 5.4 +/- 0.9 mg/dl to 6.0 +/- 1.2 mg/dl (p0.01) and a significant decrease in FEUA (p0.01). No significant differences were found in fasting plasma glucose and electrolytes levels in any of the groups.A combination therapy with a low-dose HCTZ and ARBs resulted in reduced urate excretion and elevated serum urate levels. A combination therapy with the ARB losartan was not accompanied with these effects, likely because of its inhibitory action on urate transporter 1. The study limitations deserve mention in consideration of ethic restrictions, small size, short term examination and uncontrolled design. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|